Consensus Analyst Estimated Price Target of $57.62 for Tarsus Pharmaceuticals Inc (NASDAQ:TARS) Stock
Goldman raised the price target for the Tarsus Pharmaceuticals Inc (NASDAQ:TARS) stock to “a Neutral”. The rating was released on November 20, 2023, according to finviz. The stock was initiated by Barclays, who disclosed in a research note on August 01, 2022, to Overweight and set the price objective to $40. In their research brief […]
Why Tarsus Pharmaceuticals Inc (NASDAQ:TARS) Stock went up 42.05% in Last Year?
Goldman raised the price target for the Tarsus Pharmaceuticals Inc (NASDAQ:TARS) stock to “a Neutral”. The rating was released on November 20, 2023, according to finviz. The stock was initiated by Barclays, who disclosed in a research note on August 01, 2022, to Overweight and set the price objective to $40. In their research brief […]
It’s not the right time to quit: Tarsus Pharmaceuticals Inc (TARS) Stock
Goldman raised the price target for the Tarsus Pharmaceuticals Inc (NASDAQ:TARS) stock to “a Neutral”. The rating was released on November 20, 2023, according to finviz. The stock was initiated by Barclays, who disclosed in a research note on August 01, 2022, to Overweight and set the price objective to $40. In their research brief […]
It’s an all-out bull run for Tarsus Pharmaceuticals Inc (TARS) Stock
Goldman raised the price target for the Tarsus Pharmaceuticals Inc (NASDAQ:TARS) stock to “a Neutral”. The rating was released on November 20, 2023, according to finviz. The stock was initiated by Barclays, who disclosed in a research note on August 01, 2022, to Overweight and set the price objective to $40. In their research brief […]
Tarsus Pharmaceuticals Inc (TARS) Stock at a key inflection point
Goldman raised the price target for the Tarsus Pharmaceuticals Inc (NASDAQ:TARS) stock to “a Neutral”. The rating was released on November 20, 2023, according to finviz. The stock was initiated by Barclays, who disclosed in a research note on August 01, 2022, to Overweight and set the price objective to $40. In their research brief […]
Are there any attempts to gain ground? Tarsus Pharmaceuticals Inc (TARS) Stock
Goldman raised the price target for the Tarsus Pharmaceuticals Inc (NASDAQ:TARS) stock to “a Neutral”. The rating was released on November 20, 2023, according to finviz. The stock was initiated by Barclays, who disclosed in a research note on August 01, 2022, to Overweight and set the price objective to $40. In their research brief […]
